MX360802B - Hormona de crecimiento de accion prolongada y metodos para producir la misma. - Google Patents

Hormona de crecimiento de accion prolongada y metodos para producir la misma.

Info

Publication number
MX360802B
MX360802B MX2014001335A MX2014001335A MX360802B MX 360802 B MX360802 B MX 360802B MX 2014001335 A MX2014001335 A MX 2014001335A MX 2014001335 A MX2014001335 A MX 2014001335A MX 360802 B MX360802 B MX 360802B
Authority
MX
Mexico
Prior art keywords
growth hormone
methods
long
producing same
terminal
Prior art date
Application number
MX2014001335A
Other languages
English (en)
Spanish (es)
Other versions
MX2014001335A (es
Inventor
Eyal Fima Udi
Fares Fuad
Original Assignee
Opko Biologics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Opko Biologics Ltd filed Critical Opko Biologics Ltd
Publication of MX2014001335A publication Critical patent/MX2014001335A/es
Publication of MX360802B publication Critical patent/MX360802B/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22Hormones
    • A61K38/27Growth hormone [GH], i.e. somatotropin
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475Growth factors; Growth regulators
    • C07K14/505Erythropoietin [EPO]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575Hormones
    • C07K14/59Follicle-stimulating hormone [FSH]; Chorionic gonadotropins, e.g.hCG [human chorionic gonadotropin]; Luteinising hormone [LH]; Thyroid-stimulating hormone [TSH]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22Hormones
    • A61K38/24Follicle-stimulating hormone [FSH]; Chorionic gonadotropins, e.g. HCG; Luteinising hormone [LH]; Thyroid-stimulating hormone [TSH]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Endocrinology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Reproductive Health (AREA)
  • Child & Adolescent Psychology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
MX2014001335A 2011-08-02 2012-08-02 Hormona de crecimiento de accion prolongada y metodos para producir la misma. MX360802B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US13/195,931 US8450269B2 (en) 2006-02-03 2011-08-02 Long-acting growth hormone and methods of producing same
PCT/IL2012/050288 WO2013018098A2 (en) 2011-08-02 2012-08-02 Long-acting growth hormone and methods of producing same

Publications (2)

Publication Number Publication Date
MX2014001335A MX2014001335A (es) 2016-09-26
MX360802B true MX360802B (es) 2018-11-16

Family

ID=47629749

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2014001335A MX360802B (es) 2011-08-02 2012-08-02 Hormona de crecimiento de accion prolongada y metodos para producir la misma.
MX2018014072A MX2018014072A (es) 2011-08-02 2014-01-31 Hormona de crecimiento de accion prolongada y metodos para producir la misma.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2018014072A MX2018014072A (es) 2011-08-02 2014-01-31 Hormona de crecimiento de accion prolongada y metodos para producir la misma.

Country Status (23)

Country Link
US (1) US8450269B2 (enExample)
EP (2) EP2739298B1 (enExample)
JP (1) JP6153930B2 (enExample)
KR (3) KR102028524B1 (enExample)
CN (2) CN104010650A (enExample)
AU (1) AU2012291617B2 (enExample)
BR (1) BR112014002491A2 (enExample)
CA (1) CA2843672A1 (enExample)
CL (2) CL2014000254A1 (enExample)
CO (1) CO7020850A2 (enExample)
DK (2) DK2739298T3 (enExample)
EA (2) EA202090577A3 (enExample)
ES (2) ES2983610T3 (enExample)
FI (1) FI3482765T3 (enExample)
HK (1) HK1200349A1 (enExample)
HR (1) HRP20240635T1 (enExample)
HU (2) HUE066552T2 (enExample)
MX (2) MX360802B (enExample)
PL (2) PL2739298T3 (enExample)
PT (2) PT2739298T (enExample)
SI (2) SI2739298T1 (enExample)
TR (1) TR201821186T4 (enExample)
WO (1) WO2013018098A2 (enExample)

Families Citing this family (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140113860A1 (en) 2006-02-03 2014-04-24 Prolor Biotech Ltd. Long-acting polypeptides and methods of producing and administering same
US20150038413A1 (en) 2006-02-03 2015-02-05 Opko Biologics Ltd. Long-acting polypeptides and methods of producing and administering same
US8946155B2 (en) 2006-02-03 2015-02-03 Opko Biologics Ltd. Long-acting polypeptides and methods of producing and administering same
US7553941B2 (en) 2006-02-03 2009-06-30 Modigene Inc Long-acting polypeptides and methods of producing same
US9249407B2 (en) 2006-02-03 2016-02-02 Opko Biologics Ltd. Long-acting coagulation factors and methods of producing same
US10221228B2 (en) 2006-02-03 2019-03-05 Opko Biologics Ltd. Long-acting polypeptides and methods of producing and administering same
US9458444B2 (en) 2006-02-03 2016-10-04 Opko Biologics Ltd. Long-acting coagulation factors and methods of producing same
US10351615B2 (en) 2006-02-03 2019-07-16 Opko Biologics Ltd. Methods of treatment with long-acting growth hormone
US8759292B2 (en) 2006-02-03 2014-06-24 Prolor Biotech, Llc Long-acting coagulation factors and methods of producing same
US8450269B2 (en) 2006-02-03 2013-05-28 Prolor Biotech Ltd. Long-acting growth hormone and methods of producing same
US8048849B2 (en) 2006-02-03 2011-11-01 Modigene, Inc. Long-acting polypeptides and methods of producing same
DK2279007T3 (en) 2008-04-29 2016-08-22 Ascendis Pharma Growth Disorders Div As Pegylated recombinant relations of human growth hormone
US12203113B2 (en) 2009-07-09 2025-01-21 Opko Biologics Ltd. Long-acting coagulation factors and methods of producing same
US9663778B2 (en) 2009-07-09 2017-05-30 OPKO Biologies Ltd. Long-acting coagulation factors and methods of producing same
DK2512450T3 (en) 2009-12-15 2018-04-23 Ascendis Pharma Endocrinology Div A/S Dry growth hormone composition transiently bound to a polymer carrier
JP2015520128A (ja) 2012-04-19 2015-07-16 オプコ バイオロジクス リミテッド 長時間作用性オキシントモジュリン変異体とその作製方法
ES2882890T3 (es) 2012-11-20 2021-12-03 Opko Biologics Ltd Método para aumentar el volumen hidrodinámico de polipéptidos mediante la unión a péptidos carboxi terminales de la gonadotrofina
WO2014159813A1 (en) 2013-03-13 2014-10-02 Moderna Therapeutics, Inc. Long-lived polynucleotide molecules
CN103524626B (zh) * 2013-09-27 2016-09-07 武汉龙科生物技术有限公司 重组双靶点蛋白药物及其应用
SI3060239T1 (sl) * 2013-10-21 2020-10-30 Opko Bilogics Ltd Dolgodelujoči polipeptidi ter postopki za proizvodnjo in dajanje le-teh
US20150158926A1 (en) 2013-10-21 2015-06-11 Opko Biologics, Ltd. Long-acting polypeptides and methods of producing and administering same
US10799563B2 (en) 2014-11-18 2020-10-13 Ascendis Pharma Endocrinology Division Polymeric hGH prodrugs
PL3220892T3 (pl) 2014-11-21 2022-01-31 Ascendis Pharma Endocrinology Division A/S Postacie dawkowane długo działającego hormonu wzrostu
WO2016092550A2 (en) 2014-12-10 2016-06-16 Opko Biologics Ltd. Methods of producing long acting ctp-modified polypeptides
AR102969A1 (es) * 2014-12-10 2017-04-05 Opko Biologics Ltd Métodos para producir polipéptidos modificados por ctp (péptido carboxilo terminal) de acción prolongada
EP3988113A1 (en) 2015-06-19 2022-04-27 OPKO Biologics Ltd. Long-acting coagulation factors and methods of producing same
US11224661B2 (en) 2016-01-08 2022-01-18 Ascendis Pharma Growth Disorders A/S Controlled-release CNP agonists with increased NEP stability
NZ743488A (en) 2016-01-08 2023-02-24 Ascendis Pharma Growth Disorders As Controlled-release cnp agonists with low initial npr-b activity
US11311604B2 (en) 2016-01-08 2022-04-26 Ascendis Pharma Growth Disorders A/S Controlled-release CNP agonists with low NPR-C binding
EP4162955A1 (en) 2016-01-08 2023-04-12 Ascendis Pharma Growth Disorders A/S Cnp prodrugs with carrier attachment at the ring moiety
US11389511B2 (en) 2016-01-08 2022-07-19 Ascendis Pharma Growth Disorders A/S Controlled-release CNP agonists with reduced side-effects
CA3007976C (en) 2016-01-08 2023-09-26 Ascendis Pharma Growth Disorders A/S Cnp prodrugs with large carrier moieties
SMT202400423T1 (it) 2016-03-01 2024-11-15 Ascendis Pharma Bone Diseases As Profarmaci di pth
BR112019000610A2 (pt) 2016-07-11 2019-07-02 Opko Biologics Ltd fator vii de coagulação de longa ação e métodos de produção do mesmo
WO2018011266A1 (en) 2016-07-13 2018-01-18 Ascendis Pharma A/S Conjugation method for carrier-linked prodrugs
NZ751746A (en) 2016-09-29 2023-06-30 Ascendis Pharma Growth Disorders As Combination therapy with controlled-release cnp agonists
SMT202300124T1 (it) 2016-09-29 2023-05-12 Ascendis Pharma Bone Diseases As Composti pth con bassi rapporti picco/valle
HUE070273T2 (hu) 2016-09-29 2025-05-28 Ascendis Pharma Bone Diseases As Szabályozott hatóanyag-leadású PTH vegyületek
HUE063235T2 (hu) 2016-09-29 2024-01-28 Ascendis Pharma Bone Diseases As Adagolási rendszer szabályozott leadású PTH vegyülethez
US20210008168A1 (en) 2018-03-28 2021-01-14 Ascendis Pharma A/S Conjugates
BR112020019639A2 (pt) 2018-03-28 2021-01-05 Ascendis Pharma Oncology Division A/S Conjugados de il-2
SMT202500272T1 (it) 2018-05-18 2025-09-12 Ascendis Pharma Bone Diseases As Dose iniziale di coniugati di pth
CN108676096B (zh) * 2018-05-22 2022-03-29 北京伟杰信生物科技有限公司 重组猪fsh-ctp融合蛋白及其制备方法与应用
AU2019367647B2 (en) * 2018-10-26 2026-02-26 Ethadox Ltd. Compositions and methods for biodegrading alcohol
WO2020165087A1 (en) 2019-02-11 2020-08-20 Ascendis Pharma Bone Diseases A/S Liquid pharmaceutical formulations of pth conjugates
CN113423384B (zh) 2019-02-11 2024-01-05 阿森迪斯药物生长障碍股份有限公司 Cnp缀合物的干燥药物制剂
SG11202108735QA (en) * 2019-03-04 2021-09-29 Ascendis Pharma Endocrinology Div A/S Long-acting growth hormone dosage forms with superior efficacy to daily somatropin
CA3143436A1 (en) 2019-06-21 2020-12-24 Ascendis Pharma A/S Conjugates of .pi.-electron-pair-donating heteroaromatic nitrogen-comprising compounds
WO2020254606A1 (en) 2019-06-21 2020-12-24 Ascendis Pharma A/S Conjugates of heteroaromatic nitrogen-comprising compounds
US20220304993A1 (en) 2019-06-21 2022-09-29 Ascendis Pharma A/S Conjugates of an electron-donating nitrogen or tertiary amine comprising compounds
AU2020419444A1 (en) 2020-01-03 2022-06-09 Ascendis Pharma A/S Conjugates undergoing intramolecular rearrangements
EP4090357A1 (en) 2020-01-13 2022-11-23 Ascendis Pharma Bone Diseases A/S Hypoparathyroidism treatment
IL298642A (en) 2020-06-03 2023-01-01 Ascendis Pharma Oncology Div A/S il-2 sequences and uses thereof
EP4192508A1 (en) 2020-08-05 2023-06-14 Ascendis Pharma A/S Conjugates comprising reversible linkers and uses thereof
TW202219060A (zh) 2020-08-28 2022-05-16 丹麥商阿森迪斯腫瘤製藥有限公司 醣基化il-2蛋白及其用途
JP2023543265A (ja) 2020-09-28 2023-10-13 アセンディス ファーマ ボーン ディジージズ エー/エス 副甲状腺機能低下症を有する患者の身体的及び精神的ウェルビーイングの改善
CN112175964B (zh) * 2020-10-23 2022-03-29 安徽中起生物科技有限公司 一种重组猪生长激素及其制备方法和应用
WO2022207798A1 (en) 2021-04-01 2022-10-06 Ascendis Pharma A/S Use of long-acting growth hormone for treating inflammation-induced diseases
CN114010765A (zh) * 2021-08-30 2022-02-08 上海延立药业有限公司 一种长效人生长激素
KR20240082355A (ko) 2021-09-22 2024-06-10 아센디스 파마 본 디지즈 에이/에스 장시간 작용형 pth 화합물 치료
WO2023110758A1 (en) 2021-12-13 2023-06-22 Ascendis Pharma Growth Disorders A/S Effective doses of cnp conjugates
CA3249311A1 (en) 2022-05-23 2023-11-30 Ascendis Pharma Growth Disorders A/S LIQUID PHARMACEUTICAL FORMULATIONS OF CNP COMPOUNDS
JP2025537527A (ja) 2022-11-02 2025-11-18 アセンディス ファーマ ボーン ディジージズ エー/エス 2つのpth化合物を含むpth治療レジメン
WO2024104922A1 (en) 2022-11-14 2024-05-23 Ascendis Pharma Growth Disorders A/S Method of improving skeletal muscle function
WO2024194300A1 (en) 2023-03-20 2024-09-26 Ascendis Pharma Growth Disorders A/S Method of treatment of a thoracolumbar deformity in a human subject with achondroplasia
AU2024337275A1 (en) 2023-09-04 2026-02-19 Ascendis Pharma Bone Diseases A/S Pth treatment of chronic kidney disease

Family Cites Families (84)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL154600B (nl) 1971-02-10 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van specifiek bindende eiwitten en hun corresponderende bindbare stoffen.
NL154598B (nl) 1970-11-10 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van laagmoleculire verbindingen en van eiwitten die deze verbindingen specifiek kunnen binden, alsmede testverpakking.
NL154599B (nl) 1970-12-28 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van specifiek bindende eiwitten en hun corresponderende bindbare stoffen, alsmede testverpakking.
US3901654A (en) 1971-06-21 1975-08-26 Biological Developments Receptor assays of biologically active compounds employing biologically specific receptors
US3853987A (en) 1971-09-01 1974-12-10 W Dreyer Immunological reagent and radioimmuno assay
US3867517A (en) 1971-12-21 1975-02-18 Abbott Lab Direct radioimmunoassay for antigens and their antibodies
NL171930C (nl) 1972-05-11 1983-06-01 Akzo Nv Werkwijze voor het aantonen en bepalen van haptenen, alsmede testverpakkingen.
US3850578A (en) 1973-03-12 1974-11-26 H Mcconnell Process for assaying for biologically active molecules
US3935074A (en) 1973-12-17 1976-01-27 Syva Company Antibody steric hindrance immunoassay with two antibodies
US3996345A (en) 1974-08-12 1976-12-07 Syva Company Fluorescence quenching with immunological pairs in immunoassays
US4034074A (en) 1974-09-19 1977-07-05 The Board Of Trustees Of Leland Stanford Junior University Universal reagent 2-site immunoradiometric assay using labelled anti (IgG)
US3984533A (en) 1975-11-13 1976-10-05 General Electric Company Electrophoretic method of detecting antigen-antibody reaction
US4098876A (en) 1976-10-26 1978-07-04 Corning Glass Works Reverse sandwich immunoassay
US4879219A (en) 1980-09-19 1989-11-07 General Hospital Corporation Immunoassay utilizing monoclonal high affinity IgM antibodies
JPS5781447A (en) 1980-11-11 1982-05-21 Toyo Jozo Co Ltd Human chorionic gonadotropic hormone c-terminal fragment
US4853332A (en) 1982-10-19 1989-08-01 Cetus Corporation Structural genes, plasmids and transformed cells for producing cysteine depleted muteins of biologically active proteins
US5011771A (en) 1984-04-12 1991-04-30 The General Hospital Corporation Multiepitopic immunometric assay
DE3421468A1 (de) 1984-06-08 1985-12-19 Dr. Rentschler Arzneimittel Gmbh & Co, 7958 Laupheim Lipidnanopellets als traegersystem fuer arzneimittel zur peroralen anwendung
US4666828A (en) 1984-08-15 1987-05-19 The General Hospital Corporation Test for Huntington's disease
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4801531A (en) 1985-04-17 1989-01-31 Biotechnology Research Partners, Ltd. Apo AI/CIII genomic polymorphisms predictive of atherosclerosis
DE122007000007I1 (de) 1986-04-09 2007-05-16 Genzyme Corp Genetisch transformierte Tiere, die ein gewünschtes Protein in Milch absondern
US5118666A (en) 1986-05-05 1992-06-02 The General Hospital Corporation Insulinotropic hormone
US4873316A (en) 1987-06-23 1989-10-10 Biogen, Inc. Isolation of exogenous recombinant proteins from the milk of transgenic mammals
WO1989010756A1 (fr) 1988-05-06 1989-11-16 Toray Industries, Inc. COMPOSITION D'INTERFERON beta STABLE
US5272057A (en) 1988-10-14 1993-12-21 Georgetown University Method of detecting a predisposition to cancer by the use of restriction fragment length polymorphism of the gene for human poly (ADP-ribose) polymerase
US6225449B1 (en) 1991-10-04 2001-05-01 Washington University Hormone analogs with multiple CTP extensions
AU648020B2 (en) 1989-02-21 1994-04-14 Washington University Modified forms of reproductive hormones
US5792460A (en) 1989-02-21 1998-08-11 Washington University Modified glycoprotein hormones having a CTP at the amino terminus
US5705478A (en) 1989-02-21 1998-01-06 Washington University Covalently linked β subunits of the glycoprotein hormones as antagonists
US5338835A (en) 1989-02-21 1994-08-16 Washington University CTP-extended form of FSH
US5464764A (en) 1989-08-22 1995-11-07 University Of Utah Research Foundation Positive-negative selection methods and vectors
US5192659A (en) 1989-08-25 1993-03-09 Genetype Ag Intron sequence analysis method for detection of adjacent and remote locus alleles as haplotypes
US7217689B1 (en) 1989-10-13 2007-05-15 Amgen Inc. Glycosylation analogs of erythropoietin
US5126324A (en) 1990-06-07 1992-06-30 Genentech, Inc. Method of enhancing growth in patients using combination therapy
US6028177A (en) 1991-10-04 2000-02-22 Washington University Methods of detecting single-chain forms of the glycoprotein hormone quartet
US5281521A (en) 1992-07-20 1994-01-25 The Trustees Of The University Of Pennsylvania Modified avidin-biotin technique
NZ265529A (en) 1993-04-20 1998-01-26 Univ Washington Peptide/protein modified with insertion of complete or partial carboxy terminal peptide unit into a non critical region
US6737515B2 (en) 1993-11-19 2004-05-18 Washington University Follicle stimulating hormone-glycosylation analogs
US6238890B1 (en) 1994-02-18 2001-05-29 Washington University Single chain forms of the glycoprotein hormone quartet
US5935924A (en) 1994-04-15 1999-08-10 Genentech, Inc. Treatment of congestive heart failure
US5541110A (en) 1994-05-17 1996-07-30 Bristol-Myers Squibb Cloning and expression of a gene encoding bryodin 1 from Bryonia dioica
BR9506313A (pt) 1994-08-12 1997-08-05 Univ Washington Formas de cadeia simples do quarteto de hormônio de glicoproteína
US6083725A (en) 1996-09-13 2000-07-04 Transkaryotic Therapies, Inc. Tranfected human cells expressing human α-galactosidase A protein
TW518235B (en) * 1997-01-15 2003-01-21 Akzo Nobel Nv A gonadotropin-containing pharmaceutical composition with improved stability on prolong storage
US6310183B1 (en) 1997-09-10 2001-10-30 Novo Nordisk A/S Coagulation factor VIIa composition
US6103501A (en) 1997-11-17 2000-08-15 Washington University Single chain glycoprotein hormones comprising two β and one α subunits and recombinant production thereof
EE05111B1 (et) 1998-10-16 2008-12-15 Biogen, Incorporated Interferoon-beetaga sulandatud valgud ja nende kasutamine
US6514729B1 (en) 1999-05-12 2003-02-04 Xencor, Inc. Recombinant interferon-beta muteins
JO2291B1 (en) 1999-07-02 2005-09-12 اف . هوفمان لاروش ايه جي Erythropoietin derivatives
US20020127652A1 (en) 2000-02-11 2002-09-12 Schambye Hans Thalsgard Follicle stimulating hormones
US7094566B2 (en) 2000-03-16 2006-08-22 Amgen Inc., IL-17 receptor like molecules and uses thereof
ATE416784T1 (de) 2000-12-01 2008-12-15 Takeda Pharmaceutical Verfahren zur herstellung einer zubereitung mit einer bioaktiven substanz
JP4409135B2 (ja) 2000-12-01 2010-02-03 武田薬品工業株式会社 生理活性物質含有製剤の製造法
UA93662C2 (uk) 2000-12-07 2011-03-10 Эли Лилли Энд Компани Гетерологічний пептидильований глюкагон-подібний білок та його застосування для виготовлення лікарського засобу для лікування пацієнтів, що страждають на ожиріння або інсулінонезалежний цукровий діабет
KR101229995B1 (ko) 2000-12-11 2013-02-06 씨제이 주식회사 생체내 에리스로포이에틴 활성이 증진된 융합단백질
ATE320449T1 (de) 2000-12-11 2006-04-15 Cheil Jedang Corp Fusionsprotein mit verbesserter in vivo erythropoietinwirkung
WO2002053136A1 (en) 2000-12-28 2002-07-11 Takeda Chemical Industries, Ltd. Sustained release preparations
JP5160005B2 (ja) 2000-12-28 2013-03-13 武田薬品工業株式会社 徐放性製剤
US6887462B2 (en) 2001-04-09 2005-05-03 Chiron Corporation HSA-free formulations of interferon-beta
US6824769B2 (en) 2001-08-28 2004-11-30 Vertex Pharmaceuticals Incorporated Optimal compositions and methods thereof for treating HCV infections
GB0121709D0 (en) 2001-09-07 2001-10-31 Imp College Innovations Ltd Food inhibition agent
ES2425738T3 (es) 2001-12-21 2013-10-17 Human Genome Sciences, Inc. Proteínas de fusión de la albúmina
US7081446B2 (en) 2002-01-31 2006-07-25 The Trustees Of Columbia University In The City Of New York Long-acting follicle stimulating hormone analogues and uses thereof
US7173113B2 (en) 2002-01-31 2007-02-06 The Trustees Of Columbia University In The City Of New York Long-acting hormone and growth factor compositions and uses thereof
US7459435B2 (en) 2002-08-29 2008-12-02 Hoffmann-La Roche Inc. Treatment of disturbances of iron distribution
US7459436B2 (en) 2002-11-22 2008-12-02 Hoffmann-La Roche Inc. Treatment of disturbances of iron distribution
EP1595549A4 (en) 2003-02-19 2010-09-22 Takeda Pharmaceutical DISPERSE FOR PREPARATIONS WITH DELAYED RELEASE
JP4683319B2 (ja) 2003-02-19 2011-05-18 武田薬品工業株式会社 徐放性製剤用の分散剤
CN1243022C (zh) * 2003-10-17 2006-02-22 华东师范大学 生物修饰重组人生长激素复合物及其制备方法
US7649084B2 (en) 2003-11-12 2010-01-19 University Of Georgia Research Foundation, Inc. Recombinant glycoproteins related to feline thyrotropin
JP2007514673A (ja) 2003-12-19 2007-06-07 エフ.ホフマン−ラ ロシュ アーゲー 慢性炎症性腸疾患の際の鉄分布障害の処置におけるエリスロポエチンの使用
DE602005024955D1 (de) 2004-03-19 2011-01-05 Baxter Healthcare Sa Faktor ixa zur behandlung von blutungsstörungen
MX2007001294A (es) 2004-08-17 2008-03-04 Zlb Behring Gmbh Polipeptidos modificados que dependen de vitamina k.
US8420602B2 (en) * 2004-09-14 2013-04-16 Landon C. G. Miller Endocannabinoid conjugate and a pharmaceutical composition for treatment of neuronal disorders
EP1728798A1 (en) 2005-06-01 2006-12-06 ZLB Behring GmbH Coagulation factor X polypeptides with modified activation properties
US8048849B2 (en) 2006-02-03 2011-11-01 Modigene, Inc. Long-acting polypeptides and methods of producing same
US8048848B2 (en) 2006-02-03 2011-11-01 Prolor Biotech Ltd. Long-acting interferons and derivatives thereof and methods thereof
US8476234B2 (en) 2006-02-03 2013-07-02 Prolor Biotech Inc. Long-acting coagulation factors and methods of producing same
US7553941B2 (en) 2006-02-03 2009-06-30 Modigene Inc Long-acting polypeptides and methods of producing same
US8304386B2 (en) 2006-02-03 2012-11-06 Prolor Biotech, Inc. Long-acting growth hormone and methods of producing same
US8450269B2 (en) 2006-02-03 2013-05-28 Prolor Biotech Ltd. Long-acting growth hormone and methods of producing same
KR100900784B1 (ko) * 2007-01-03 2009-06-02 주식회사 하이닉스반도체 반도체메모리소자
WO2009114959A1 (zh) * 2008-03-20 2009-09-24 中国人民解放军军事医学科学院毒物药物研究所 可注射用缓释药物制剂及其制备方法

Also Published As

Publication number Publication date
DK3482765T3 (da) 2024-05-21
US20120035101A1 (en) 2012-02-09
KR20210013300A (ko) 2021-02-03
MX2018014072A (es) 2021-11-16
HUE066552T2 (hu) 2024-08-28
PT3482765T (pt) 2024-05-23
EA202090577A3 (ru) 2021-06-30
AU2012291617A1 (en) 2014-02-20
MX2014001335A (es) 2016-09-26
EP2739298A2 (en) 2014-06-11
FI3482765T3 (fi) 2024-05-16
HRP20240635T1 (hr) 2024-08-02
DK2739298T3 (en) 2019-01-28
KR102028524B1 (ko) 2019-10-04
EP2739298B1 (en) 2018-10-03
PL2739298T4 (pl) 2019-05-31
US8450269B2 (en) 2013-05-28
HUE042755T2 (hu) 2019-07-29
HK1200349A1 (en) 2015-08-07
SI3482765T1 (sl) 2024-06-28
EP3482765B1 (en) 2024-02-28
CL2014000254A1 (es) 2015-01-16
AU2012291617B2 (en) 2017-07-06
SI2739298T1 (sl) 2019-03-29
PL2739298T3 (pl) 2019-05-31
CN107080835A (zh) 2017-08-22
PL3482765T3 (pl) 2024-08-26
KR20140083973A (ko) 2014-07-04
CO7020850A2 (es) 2014-08-11
PT2739298T (pt) 2019-01-11
ES2706734T3 (es) 2019-04-01
EA035352B1 (ru) 2020-06-01
EP2739298A4 (en) 2015-03-25
TR201821186T4 (tr) 2019-01-21
JP2014521684A (ja) 2014-08-28
JP6153930B2 (ja) 2017-06-28
WO2013018098A3 (en) 2013-05-10
EP3482765A1 (en) 2019-05-15
CN104010650A (zh) 2014-08-27
WO2013018098A2 (en) 2013-02-07
ES2983610T3 (es) 2024-10-23
BR112014002491A2 (pt) 2017-02-21
CA2843672A1 (en) 2013-02-07
EA201490393A1 (ru) 2015-01-30
DK3482765T5 (da) 2024-09-02
CL2020002010A1 (es) 2020-12-18
EA202090577A2 (ru) 2021-03-31
KR20190116526A (ko) 2019-10-14

Similar Documents

Publication Publication Date Title
MX2018014072A (es) Hormona de crecimiento de accion prolongada y metodos para producir la misma.
GEP20176629B (en) Glucagon/glp-1 receptor co-agonists
MX358161B (es) Analogos de hormona paratiroidea y usos para los mismos.
PH12014501336A1 (en) Glucagon analogues
MY188182A (en) Acylated glucagon analogues
IL223867B (en) Recombinant human follicle stimulating hormone, compositions comprising the same and uses thereof
EA201291234A1 (ru) Аналоги глюкагона
WO2010149752A3 (en) Novel human papillomavirus (hpv) protein constructs and their use in the prevention of hpv disease
AR092456A1 (es) Proteinas de fusion para el tratamiento de un sindrome metabolico
IL216680A (en) Growth hormone fusion protein containing human growth hormone attached to an elongated polypeptide
HK1208629A1 (en) Hgh-xten fusion protein and its use in the treatment of growth hormone deficiency
PE20151612A1 (es) Polipeptidos estabilizados del factor de crecimiento tipo insulina
WO2012127501A3 (en) Composition for improving endometrial thickness during ovarian stimulation
NZ598600A (en) Therapeutic agent for rhinitis
WO2013090770A3 (en) Delivery of therapeutic agents by a collagen binding protein
MD20120127A2 (en) Recombinant Koi herpesvirus (KHV), method for its production and vaccine for the prevention of a disease caused by KHV
NZ629004A (en) Combination therapy comprising a growth hormone variant and an oligonucleotide targeted to the growth hormone receptor
EA201690490A1 (ru) Миметики инсулиноподобного фактора роста для применения в терапии
MX2021003908A (es) Polipeptidos de accion prolongada y metodos para su produccion y administracion.
MX362533B (es) Combinacion de analogos de somatostatina con inhibidores de 11-beta-hidroxilasa.
UA118653C2 (uk) Суперагоністи глікопротеїнового гормону тривалої дії
CL2015002299A1 (es) Composición alimenticia y uso de la misma para balance proteico
MX2013012259A (es) Analogos del factor de liberacion de la hormona de crecimiento (grf) y usos de estos.
GB2522163A (en) Fat loss composition
CU20160082A7 (es) Un proceso para la preparación de una composición de proteínas pegiladas

Legal Events

Date Code Title Description
FG Grant or registration